Larimar Therapeutics shares are trading higher after Wedbush initiated coverage on the stock with an Outperform rating and announced a price target of $22.
Portfolio Pulse from Benzinga Newsdesk
Larimar Therapeutics shares rose after Wedbush initiated coverage with an Outperform rating and set a price target of $22.
October 03, 2024 | 3:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Larimar Therapeutics shares increased following Wedbush's initiation of coverage with an Outperform rating and a $22 price target.
The initiation of coverage by Wedbush with an Outperform rating and a specific price target of $22 is a positive signal to investors, likely leading to increased buying interest and a rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100